ANDA User Fee Negotiations: A Big-Firm Coalition Tackles The Big Backlog
Executive Summary
FDA has long negotiated its brand user fee program with two distinct but closely aligned industry groups: the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. Now the agency will be using those same discussion techniques as it develops the generic drug user fee program.
You may also be interested in...
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected
The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.
"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected
The prospect of FDA obtaining a combined bill reauthorizing existing user fee programs and creating two others could be challenging, given that some negotiations have yet to begin and agreements may not be completed fast enough to meet congressional time tables.
Hospira The Holdout
The Generic Pharmaceutical Association's reunification is not entirely complete. Hospira, alone among large firms that had left the association, has opted to remain a former member.